News

Article

February 13, 2025

Daily Derm Times: February 13, 2025

Author(s):

Urticaria subtypes and emerging therapies, including dupilumab and remibrutinib, are explored for improved treatment strategies.
Tailored approaches for atopic dermatitis management emphasize balancing biologics and corticosteroids.
A study investigates the relationship between formulation and benzene levels in benzoyl peroxide products.
Allergan Medical Institute is expanding its curriculum with new training centers in California, Georgia, and Texas.
Dermatology industry trends, including mergers, acquisitions, and economic shifts, are shaping the future landscape.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Hawkes discusses urticaria subtypes, treatments, and emerging therapies like dupilumab and remibrutinib.

Alexandra Golant, MD, led a Dermatology Times Case-Based Roundtable® event that focused on advancing therapeutic strategies for atopic dermatitis.

Are you attending Winter Clinical Hawaii? Answer our poll below to let us know.

Barbieri et al evaluated product use, benzoyl peroxide concentration, days until expiration, and more.

The state-of-the-art facilities in California, Georgia, and Texas will expand AMI’s curriculum to providers of all levels.

Explore 2025’s dermatology M&A trends, economic shifts, and key investment drivers shaping the industry's future.

Renata Block, MMS, PA-C, and Michael Rubio, PA-C discuss the complexities of developing a telehealth program in the world of dermatology.